Mease, P.J., Chohan, S., Garcia Fructuoso, F.J., Gottlieb, A.B., Chou, R.C., Mendelsohn, A.M. and Luggen, M.E. 2020. Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis. SKIN The Journal of Cutaneous Medicine. 4, 5 (Sep. 2020), s43. DOI:https://doi.org/10.25251/skin.4.supp.43.